Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
-
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018
Juluca, the first 2-drug regimen, once daily, single pill regimen, maintains viral suppression through 100 weeks.
-
ViiV Healthcare presents phase III data at AIDS 2018 from landmark GEMINI studies showing two-drug regimen of dolutegravir and lamivudine has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no emergence of resistance
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads.
-
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
-
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018
ViiV, specialist HIV company will be presenting over 20 abstracts, including GEMINI 1 & 2 trials, at the AIDS 2018 in Amsterdam.
-
US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
There is substantial evidence of the effectiveness and adequate evidence of the safety of single-dose tafenoquine
-
James Ford appointed GSK General Counsel
James Ford, currently SVP and General Counsel for Global Pharma, will succeed Dan Troy as General Counsel, GSK.
-
Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK today announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof.
-
GSK announce...
GSK announce...
-
Infants may now be protected against Meningitis B with fewer doses, adding flexibility to vaccination schedules
Healthcare professionals now have more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B
-
ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients
GEMINI 1&2 studies meet primary endpoint, demonstrating similar efficacy of two-drug regimen compared to standard three-drug regimen
-
GSK presents new results showing low rates of organ damage with long term use of Benlysta
Results showing low rates of organ damage progression in patients with active systemic lupus erythematosus treated with Benlysta
-
GSK announces changes to Vaccines and Global Manufacturing & Supply leadership
Luc Debruyne, President, Vaccines, is to leave GSK at the end of the year.
-
GSK completes Consumer Healthcare buyout
GSK has completed the buyout of Novartis’ 36.5% stake in its Consumer Healthcare Joint Venture for $13 billion (£9.3 billion*).
-
GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and W...
-
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV
Juluca maintains viral suppression with two drugs in the smallest single pill regimen
-
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta
-
Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control
New study showed one third of patients had no exacerbations on long-term treatment with Nucala.
-
GSK’s industry-leading respiratory research and scientific innovation showcased at ATS conference
GlaxoSmithKline plc (GSK) will present at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018.
-
Simon Dingemans, Chief Financial Officer, to retire from GSK
Simon Dingemans, Chief Financial Officer, GSK, has informed the Board of his intention to retire from the Company in May 2019.
